← Back to Screener
BioLineRX Ltd (BLRX)
Price$2.39
Favorite Metrics
Price vs S&P 500 (26W)-51.81%
Price vs S&P 500 (4W)-25.82%
Market Capitalization$33.94M
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)9.42x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.01
Price vs S&P 500 (YTD)-26.78%
Gross Margin (TTM)50.69%
Net Profit Margin (TTM)-23.38%
EPS (TTM)$-0.00
10-Day Avg Trading Volume3.13M
EPS Excl Extra (TTM)$-0.00
EPS (Annual)$-0.01
ROI (Annual)-32.35%
Gross Margin (Annual)67.99%
Cash / Share (Quarterly)$0.01
Revenue Growth QoQ (YoY)-91.36%
ROA (Last FY)-23.70%
Revenue Growth TTM (YoY)-42.09%
EBITD / Share (TTM)$0.00
ROE (5Y Avg)-150.40%
Operating Margin (TTM)-88.94%
Cash Flow / Share (Annual)$-0.03
P/B Ratio0.58x
P/B Ratio (Quarterly)1.02x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.16x
Net Interest Coverage (TTM)-0.28x
ROA (TTM)-7.20%
EV / EBITDA (TTM)4.44x
EPS Incl Extra (Annual)$-0.01
Current Ratio (Annual)1.76x
Quick Ratio (Quarterly)1.90x
3-Month Avg Trading Volume4.34M
52-Week Price Return136.20%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)0.39x
Asset Turnover (Annual)0.74x
52-Week High$3.90
EPS Excl Extra (Annual)$-0.01
CapEx CAGR (5Y)-5.85%
Tangible BV CAGR (5Y)-31.07%
26-Week Price Return-47.83%
Quick Ratio (Annual)1.53x
13-Week Price Return-25.00%
Total Debt / Equity (Annual)1.12x
Current Ratio (Quarterly)2.09x
Enterprise Value$14.723
Asset Turnover (TTM)0.31x
Book Value / Share Growth (5Y)-44.68%
Revenue / Employee (Annual)$1
Pretax Margin (Annual)-31.86%
Cash / Share (Annual)$0.01
3-Month Return Std Dev76.94%
Net Income / Employee (TTM)$-0
ROE (Last FY)-68.50%
Net Interest Coverage (Annual)0.52x
EPS Basic Excl Extra (Annual)$-0.01
Receivables Turnover (TTM)7.05x
Total Debt / Equity (Quarterly)0.58x
EPS Incl Extra (TTM)$-0.00
ROI (TTM)-9.40%
P/S Ratio (TTM)0.88x
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.00
Price vs S&P 500 (52W)149.95%
Year-to-Date Return-25.00%
5-Day Price Return-7.69%
EPS Normalized (Annual)$-0.01
ROA (5Y Avg)-49.58%
Net Profit Margin (Annual)-31.86%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-0.18
EBITD / Share (Annual)$-0.00
Operating Margin (Annual)-70.52%
LT Debt / Equity (Annual)0.67x
ROI (5Y Avg)-90.87%
LT Debt / Equity (Quarterly)0.29x
EPS Basic Excl Extra (TTM)$-0.00
P/TBV (Quarterly)2.18x
P/B Ratio (Annual)2.11x
Inventory Turnover (TTM)2.19x
Pretax Margin (TTM)-23.38%
Book Value / Share (Annual)$0.01
Price vs S&P 500 (13W)-25.69%
Beta0.16x
P/FCF (Annual)1.10x
Revenue / Share (TTM)$0.00
ROE (TTM)-16.11%
52-Week Low$1.20
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BLRXBioLineRX Ltd | 0.88x | -42.09% | 50.69% | — | $2.39 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
BioLine Rx is a commercial-stage biopharmaceutical company developing oncology-focused therapies. The company's pipeline includes two clinical-stage candidates: motixafortide (BL-8040), a peptide targeting stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent for solid tumors. The company also maintains a legacy product, BL-5010, for skin lesions, and has generated revenue through milestone payments and out-licensing agreements.